Oritavancin
- Generic Name
- Oritavancin
- Brand Names
- Kimyrsa, Orbactiv, Tenkasi (previously Orbactiv)
- Drug Type
- Small Molecule
- Chemical Formula
- C86H97Cl3N10O26
- CAS Number
- 171099-57-3
- Unique Ingredient Identifier
- PUG62FRZ2E
- Background
Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts the option of single-dose administratio...
- Indication
用于治疗由下列易感分离株革兰氏阳性微生物所致急性细菌皮肤和皮肤结构感染(ABSSSI)成年患者的治疗。如金黄色葡萄球菌(包括甲氧西林-易感和甲氧西林–耐药分离株)，化脓性链球菌，无乳链球菌，停乳链球菌，咽峡炎链球菌群(包括咽颊炎链球菌，中间型链球菌,和星座链球菌)，和粪肠球菌(万古霉素-仅易感分离株)。
- Associated Conditions
- Skin and skin structure infections
- Associated Therapies
- -
Study to Evaluate the Safety and Tolerability of Single-Dose Intravenous (IV) Oritavancin
- Conditions
- Interventions
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Melinta Therapeutics, LLC
- Target Recruit Count
- 200
- Registration Number
- NCT05599295
- Locations
- 🇧🇬
University Multiprofile Hospital For Active Treatment Kanev AD, Ruse, Bulgaria
🇷🇴Louis Turcanu Emergency Clinical Hospital for Children, Timisoara, Timis, Romania
🇵🇹Hospital de Braga, Braga, Portugal
Anchoring Sequential Intermittent Long Acting Antimicrobials With Medication for Opioid Use Disorder (MOUD) for Invasive Infections Related to Opioid Use
- Conditions
- Interventions
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 25
- Registration Number
- NCT05521880
- Locations
- 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients
- Conditions
- Interventions
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT03873987
- Locations
- 🇺🇸
ML-ORI-102 Study Site, Somers Point, New Jersey, United States
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
- First Posted Date
- 2017-05-18
- Last Posted Date
- 2018-03-12
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 325
- Registration Number
- NCT03159403
- Locations
- 🇺🇸
Birmingham Infectious Disease and Infusion, Birmingham, Alabama, United States
🇺🇸St. Vincent Hospital and Health Care Center, Inc., Indianapolis, Indiana, United States
🇺🇸Santa Barbara Cottage Hospital, Santa Barbara, California, United States
Safety of Either a Single or Two Intravenous Doses of Orbactiv in Participants With Acute Bacterial Skin and Skin Structure Infection
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 22
- Registration Number
- NCT02925416
- Locations
- 🇺🇸
South Jersey Infectious Disease, Somers Point, New Jersey, United States
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy Volunteers
- First Posted Date
- 2015-06-15
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 56
- Registration Number
- NCT02471690
- Locations
- 🇺🇸
Spaulding Clinical, West Bend, Wisconsin, United States
Multiple Oritavancin Doses on Safety, Tolerability, and Pharmacokinetics in Healthy Subjects
- First Posted Date
- 2015-06-12
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT02470702
A Study to Evaluate the Safety of a Single Intravenous (IV) Dose of Orbactiv (Oritavancin) in Participants on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
- Conditions
- Interventions
- First Posted Date
- 2015-05-25
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 17
- Registration Number
- NCT02452918
Oritavancin on the Results of Multiple Coagulation Tests in Healthy Volunteers
- First Posted Date
- 2015-02-06
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02357524
Open-Label, Dose-Finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Patients With Suspected or Confirmed Bacterial Infections
- First Posted Date
- 2014-05-09
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Melinta Therapeutics, LLC
- Target Recruit Count
- 52
- Registration Number
- NCT02134301
- Locations
- 🇺🇸
Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States
🇺🇸UCLA Harbor Medical Center, Torrance, California, United States
🇺🇸Stony Brook University Medical Center, Stony Brook, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.